2024
The Role of 3’ Regulatory Region Flanking Kinectin 1 Gene in Schizophrenia
Guo X, Luo X, Huang X, Zhang Y, Ji J, Wang X, Wang K, Wang J, Pan X, Chen B, Tan Y, Luo X. The Role of 3’ Regulatory Region Flanking Kinectin 1 Gene in Schizophrenia. ALPHA PSYCHIATRY 2024, 25: 413-420. PMID: 39148597, PMCID: PMC11322729, DOI: 10.5152/alphapsychiatry.2024.241616.Peer-Reviewed Original ResearchGray matter volumeAssociated with volumetric reductionsBasal gangliaSuperior frontal cortexDevelopment of schizophreniaSingle-nucleotide polymorphismsRisk of schizophreniaNucleus accumbensFrontal cortexPosterior cingulateMatter volumeInsular cortexBrain areasSchizophreniaSubcortical nucleiVolumetric reductionCortexPutamenCortical areasIndependent samplesRisk allelesSignificance of variantsRegulatory regionsMRNA expressionGenome-wide association studies
2023
Clustering Schizophrenia Genes by Their Temporal Expression Patterns Aids Functional Interpretation
van der Meer D, Cheng W, Rokicki J, Fernandez-Cabello S, Shadrin A, Smeland O, Ehrhart F, Gülöksüz S, Pries L, Lin B, Rutten B, van Os J, O’Donovan M, Richards A, Steen N, Djurovic S, Westlye L, Andreassen O, Kaufmann T, Aguilar E, Akdede B, Alptekin K, Altınyazar V, Amoretti S, Andric-Petrovic S, Arango C, Arrojo M, Atbaşoğlu C, Bernardo M, Binbay T, Bobes J, Cankurtaran E, Carracedo A, Cihan B, Delespaul P, García-Portilla M, González-Peñas J, Guloksuz S, Gümüş-Akay G, Jiménez-López E, Ulusoy Kaymak S, Kenis G, Lin B, López G, Luykx J, Maric N, Mezquida G, Mihaljevic M, Mirjanic T, Parellada M, Pries K, Rivero O, Rutten B, Saiz P, Can Saka M, Sanjuan J, Luis Santos J, Soygür H, Üçok A, Ulaş H, van Os J, Yalınçetin B, Alizadeh B, van Amelsvoort T, Cahn W, de Haan L, Schirmbeck F, van Os J, Veling W. Clustering Schizophrenia Genes by Their Temporal Expression Patterns Aids Functional Interpretation. Schizophrenia Bulletin 2023, 50: 327-338. PMID: 37824720, PMCID: PMC10919784, DOI: 10.1093/schbul/sbad140.Peer-Reviewed Original ResearchAge-matched healthy controlsBrain maturational processesIndependent clinical cohortsOnset of symptomsPolygenic riskCortical tissue samplesGenetic risk factorsDevelopment of schizophreniaHeritable brain disorderSymptom onsetHealthy controlsRisk factorsClinical cohortEarly neurodevelopmentPolygenic risk scoresRisk scoreImmune systemSchizophrenia diagnosisBrain disordersSchizophreniaNeuronal communicationStrong associationEarly adulthoodTissue samplesMaturational processes
2014
Positive and negative schizotypy are associated with prodromal symptoms, schizophrenia-spectrum symptoms and personalities, and self and other schemas
Kwapil T, Barrantes-Vidal N, Gross G, Sheinbaum T, Mitjavila M, Ballespí S. Positive and negative schizotypy are associated with prodromal symptoms, schizophrenia-spectrum symptoms and personalities, and self and other schemas. Personality And Individual Differences 2014, 60: s7. DOI: 10.1016/j.paid.2013.07.166.Peer-Reviewed Original ResearchSchizophrenia-spectrum personality disordersDevelopment of schizophreniaPresent studyProdromal symptomsSchizophrenia prodromeMood symptomsRelated disordersSymptomsSchizoid symptomsYoung adultsPersonality disorderSchizophrenia-spectrum symptomsInterview measuresDisordersPrevious findingsThreshold statusCAARMSProdromeEtiologyChapter Fourteen Cannabis, Cannabinoids, and the Association with Psychosis
Radhakrishnan R, Addy P, Sewell R, Skosnik P, Ranganathan M, D’Souza D. Chapter Fourteen Cannabis, Cannabinoids, and the Association with Psychosis. 2014, 423-474. DOI: 10.1016/b978-0-12-418679-8.00014-9.Peer-Reviewed Original ResearchPsychotic disordersCannabis exposureComponent causesCannabinoid receptor functionDevelopment of schizophreniaHeavy cannabis exposurePublic health policyCannabinoid exposureTrigger relapsePsychophysiological deficitsCognitive symptomsReceptor functionSchizophreniaHealth policyCannabinoidsPsychosisCannabisLines of evidenceDisordersFurther studiesSymptomsBiological mechanismsExposureIndividual vulnerabilityCause
2013
Prediction of Psychopathology and Functional Impairment by Positive and Negative Schizotypy in the Chapmans’ Ten-Year Longitudinal Study
Kwapil T, Gross G, Silvia P, Barrantes-Vidal N. Prediction of Psychopathology and Functional Impairment by Positive and Negative Schizotypy in the Chapmans’ Ten-Year Longitudinal Study. Journal Of Psychopathology And Clinical Science 2013, 122: 807-815. PMID: 24016018, DOI: 10.1037/a0033759.Peer-Reviewed Original ResearchConceptsNegative schizotypyPredictive validityPrediction of psychopathologyLongitudinal dataTen-year longitudinal studyNegative symptom dimensionsSchizophrenia spectrum disordersMental health treatmentPoor adjustmentSocial impairmentValidity findingsSchizoid symptomsRecent cross-sectional studySchizotypyCross-sectional studySymptom dimensionsControl participantsDevelopment of schizophreniaPositive dimensionUseful constructHealth treatmentParanoid symptomsMultidimensional structureLongitudinal studyDifferential patternsPositive and negative schizotypy are associated with prodromal and schizophrenia-spectrum symptoms
Barrantes-Vidal N, Gross G, Sheinbaum T, Mitjavila M, Ballespí S, Kwapil T. Positive and negative schizotypy are associated with prodromal and schizophrenia-spectrum symptoms. Schizophrenia Research 2013, 145: 50-55. PMID: 23402694, DOI: 10.1016/j.schres.2013.01.007.Peer-Reviewed Original ResearchConceptsSchizophrenia-spectrum personality disordersDevelopment of schizophreniaPositive schizotypy dimensionNegative symptom dimensionsPresent studySchizophrenia prodromeMood symptomsRelated disordersYoung adultsSchizoid symptomsSymptomsPersonality disorderSchizophrenia-spectrum symptomsSymptom dimensionsInterview measuresSpanish young adultsDisordersPrevious findingsThreshold statusQuestionnaire measuresCAARMSProdromeProdromalEtiologyFindings
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply